The Lancet Oncology

Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study

Pub Date : 2025-09-08 DOI: 10.1016/s1470-2045(25)00480-2 Kelly G Paulson, Sally C M Lau, Myung-Ju Ahn, Mor Moskovitz, Michael Pogorzelski, Simon Häfliger, Amanda Parkes, Yuyang Zhang, Ali Hamidi, Corbin G Thompson, Martin Wermke

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial

Pub Date : 2025-09-05 DOI: 10.1016/s1470-2045(25)00379-1 Cathalijne C B Post, Stephanie M de Boer, Melanie E Powell, Linda Mileshkin, Dionyssios Katsaros, Paul Bessette, Alexandra Leary, Petronella B Ottevanger, Mary McCormack, Pearly Khaw, Romerai D'Amico, Anthony Fyles, Cyrus Chargari, Henry C Kitchener, Viet Do, Andrea Lissoni, Diane Provencher, Catherine Genestie, Hans W Nijman, Karen Whitmarsh, Carien L Creutzberg

Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial

Pub Date : 2025-09-04 DOI: 10.1016/s1470-2045(25)00380-8 Chad Tang, Alexander D Sherry, Aaron Seo, Kieko Hara, Haesun Choi, Suyu Liu, Xiaowen Sun, Anya Montoya, Ethan B Ludmir, Amishi Y Shah, Eric Jonasch, Amado J Zurita, Craig Kovitz, Omar Alhalabi, Sangeeta Goswami, Andrew W Hahn, Matthew T Campbell, Arianna Hernandez, Kevin T Nead, Peter Van Loo, Pavlos Msaouel